US Pharma MarketingUS patent infringement investigation targets German drug price control measures - Pharmaceutical Technology
The Office of the US Trade Representative (USTR) has triggered a new active investigation targeting Germany over what it describes as "persistent underpayment for innovative medicines” and other policies discriminatory to US commerce. If investigators uncover violations, this could enable the USTR to pursue unilateral action against Germany. The USTR decision to open a Section 301 investigation into pharmaceutical pricing and reimbursement policies in Germany is part of an escalating pattern of US executive orders. Credit: Mark Van Scyoc / Shutterstock.com. The Office of the US Trade Representative (USTR) has triggered a new active investigation targeting Germany over what it…
The Office of the US Trade Representative (USTR) has triggered a new active investigation targeting Germany over what it describes as "persistent underpayment for innovative medicines” and other policies discriminatory to US commerce.
Source: Pharmaceutical Technology